NEW YORK (GenomeWeb) – Novigenix has signed a commercialization agreement with Dr Risch Medical Laboratory to distribute its PCR-based Colox blood test for early detection of colorectal cancer, giving the firm access to the Swiss German market and Lichtenstein.

The agreement comes after a similar one with Unilabs to target the French Swiss market and is part of the firm's overall European expansion plans.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.